Halozyme Therapeutics holds the cleaner structural position, with the lead spread across growth and valuation. Camurus AB (publ) still leads on profitability and stability, which keeps the comparison from looking entirely one-sided. On the market side, Halozyme Therapeutics is in better shape — its trend is intact while Camurus AB (publ)'s trend has broken down. That puts structure and market broadly in agreement — Halozyme Therapeutics's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (CAMX.ST: STOXX 600, HALO: Russell 1000).
Most of the lead runs through growth, while valuation helps make the separation broader. Halozyme Therapeutics, Inc. leads by 17 points on the overall comparison score.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. CAMX.ST and HALO share the same industry classification.
For a similarity-based comparison, see how Camurus AB (publ) and Halozyme Therapeutics each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Halozyme Therapeutics, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where CAMX.ST and HALO each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.
Stability is the one area where Camurus AB (publ) still pushes back materially — it is the steadier name on this dimension, which keeps the result from reading as one-way.
The lead is built on both growth and valuation — though profitability still provides a counterweight.
Break down the CAMX.ST vs HALO comparison across all dimensions with the full interactive tool.
Explore how CAMX.ST and HALO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.